Stemmer, Salomon M.
Steiner, Mariana
Rizel, Shulamith
Geffen, David B.
Nisenbaum, Bella
Peretz, Tamar
Soussan-Gutman, Lior
Bareket-Samish, Avital
Isaacs, Kevin
Rosengarten, Ora
Fried, Georgeta
McCullough, Debbie
Svedman, Christer
Shak, Steven
Liebermann, Nicky
Ben-Baruch, Noa
Article History
Received: 1 March 2017
Revised: 27 June 2017
Accepted: 3 July 2017
First Online: 8 September 2017
Competing interests
: Salomon M. Stemmer reports receiving grant funding from Teva; receiving travel expenses from Genomic Health, Inc; and conducting research funded by Teva. Lior Soussan-Gutman reports being employed by and holding stock options in Teva Pharmaceutical Industries Ltd. Avital Bareket-Samish reports being a consultant/medical writer for Teva Pharmaceutical Industries Ltd, Genomic Health Inc (including for the purpose of the current analysis), Bayer, and Roche. Christer Svedman, Debbie McCullough, and Steven Shak report being employed by Genomic Health and having stock ownership in Genomic Health. Christer Svedman, and Steven Shak report having intellectual property interest in Genomic Health. Steven Shak reports having a leadership role at Genomic Health. Noa Ben-Baruch reports receiving honoraria from Teva, and serving on the speaker’s bureau of Genomic Health. Marian Steiner, Shulamith Rizel, David B Geffen, Bella Nisenbaum, Tamar Peretz, Kevin Isaacs, Ora Rosengarten, Georgeta Fried, and Nicky Liebermann declare no competing financial interests.